

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5562087

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SEAN MARK DALZIEL	06/03/2019
RECEIVING PARTY DATA	
Name:	GLOBAL BLOOD THERAPEUTICS, INC.
Street Address:	171 OYSTER POINT BLVD.
Internal Address:	SUITE 300
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15782381
PCT Number:	US2017056352
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	bdinh@smrh.com, svipdocketing@smrh.com
Correspondent Name:	SHEPPARD MULLIN RICHTER & HAMPTON
Address Line 1:	379 LYTTON AVENUE
Address Line 2:	LORNA L. TANNER
Address Line 4:	PALO ALTO, CALIFORNIA 94301
ATTORNEY DOCKET NUMBER:	259622-US; 259622-WO
NAME OF SUBMITTER:	LORNA L. TANNER
SIGNATURE:	/Lorna L. Tanner/
DATE SIGNED:	06/07/2019
Total Attachments: 9	
source=GBT-16-003-US_Executed_Assignment_Seal_Mark_Dalziel#page1.tif	
source=GBT-16-003-US_Executed_Assignment_Seal_Mark_Dalziel#page2.tif	
source=GBT-16-003-US_Executed_Assignment_Seal_Mark_Dalziel#page3.tif	
source=GBT-16-003-US_Executed_Assignment_Seal_Mark_Dalziel#page4.tif	

source=GBT-16-003-US_Executed_Assignment_Sean_Mark_Dalziel#page5.tif
source=GBT-16-003-US_Executed_Assignment_Sean_Mark_Dalziel#page6.tif
source=GBT-16-003-US_Executed_Assignment_Sean_Mark_Dalziel#page7.tif
source=GBT-16-003-US_Executed_Assignment_Sean_Mark_Dalziel#page8.tif
source=GBT-16-003-US_Executed_Assignment_Sean_Mark_Dalziel#page9.tif

**CONFIRMATORY PATENT ASSIGNMENT
BY SEAN MARK DALZIEL**

This CONFIRMATORY PATENT ASSIGNMENT, is made by and between Sean Mark Dalziel ("Assignor") and Global Blood Therapeutics, Inc. ("Assignee"), a Delaware corporation.

WHEREAS, Assignor, further to the Master Services Agreement entered into as of November 10, 2015, between Cleo Life Sciences, a Limited Liability Delaware Corporation with a main address at 1220 Balboa Avenue, Burlingame, California 94010 and Assignee, executed an Assignment Agreement with Global Blood Therapeutics, Inc., effective November 7, 2016, (the "Assignment Agreement") whereby Assignor fully assigned all of his right, title and interest in the Application No. **62/407,406**, filed October 12, 2016 to Assignee;

WHEREAS, Assignor has invented certain new and useful improvements in "TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE" set forth in Application No. **62/407,406**, filed October 12, 2016, and also the patents and patent applications identified on attached *Schedule A* (the "Assigned Patent Applications"); and

WHEREAS, the undersigned parties desire to confirm the assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned parties agree as follows:

1. With respect to the Assigned Patent Applications, Assignor does hereby confirm that, effective as of November 7, 2016, the date of the Assignment Agreement ("Assignment Date"), Assignor irrevocably assigned all of his right, title and interest to the Assignee, and Assignor hereby confirms the sale, transfer, assignment and delivery of, and Assignee hereby confirms the assumption and acceptance of, effective as of the applicable "Assignment Date" pursuant to the terms of the Assignment Agreement, all of Assignor's worldwide right, title, and interest in and to: (a) such Assigned Patent Applications, together with all registrations and applications for the foregoing; and all rights to request, apply for, file and register patent rights in any of the foregoing; (b) all applications, including provisional applications, continuation applications, divisional applications, substitute applications and continuation-in-part applications claiming the benefit of the filing date of or priority to the foregoing; all patents of addition of the foregoing; all continued examinations, re-examinations, inter partes review and post-grant review certificates of the foregoing; (c) all validations, supplementary perfection certifications and extensions of the foregoing; (d) all inventions disclosed or claimed by any of the foregoing; (e) all rights to claim priority to the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, and applicable bilateral or

multilateral treaties; (f) all patents issuing from the foregoing and all amendments, reissues, and extensions of the foregoing; (g) all defenses relating to or arising from any of the foregoing, and all rights of actions arising from the foregoing, including without limitation all claims for damages by reason of infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing; and (h) all income, royalties and any other payments now and hereafter due and/or payable to in respect of the foregoing, in each case, to be held and enjoyed by Assignee for its own use and benefit and for its successors legal representatives and assigns as the same would have been held as fully and entirely by Assignor had this assignment not been made (collectively, the "Assigned Patent Application Rights").

2. Assignor hereby confirms that, at the time of invention, except for any rights, titles and/or interests that have arisen to Assignee under law or that had already been transferred to Assignee, Assignor is the sole and lawful owner of the entire right, title and interest in and to the said Assigned Patent Applications, and that the Assignor was unencumbered and had good and full right and lawful authority to convey the same to Assignee.

3. To the extent that any of his rights to the Assigned Patent Applications were not assigned, Assignor hereby assigns, effective as of November 7, 2016, all of his right, title and interest to the Assigned Patent Applications to the Assignee, including the Assigned Patent Application Rights.

4. Assignor shall promptly execute and deliver such documents, and do and perform such acts and things as Assignee, its successors, legal representatives and/or assigns may reasonably request to give effect to, document and record, and enforce the assignment of the Assigned Patent Application Rights herein recited, including without limitation executing and delivering such other documents as may be required to give full effect to the rights of Assignee, its successors, legal representatives and assigns under this Patent Assignment in and to the Assigned Patent Application Rights worldwide.

5. Assignor further agrees, at any time, upon the reasonable request of Assignee, its successors, legal representatives and/or assigns, to execute and deliver same, any additional applications for patent arising from or relating to the Assigned Patent Application Rights, or any part or parts thereof, including without limitation any provisional, utility, design, continuation, continuation-in-part, divisional, reissue, substitute, and extension application(s) to the foregoing; and all re-examination, inter partes, postgrant and opposition certification(s) or amendments or reissues of the foregoing and all patent application(s) claiming benefit of or priority from the foregoing; and all patents issued from the foregoing. Assignor further confirms that Assignor has not made any agreement in conflict with this Patent Assignment.

6. Assignor hereby grants Assignee the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document.

7. This Patent Assignment may be executed in the original or by facsimile in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

As read and agreed to by:

Sean Mark Dalziel ("Assignor")

See attached California
Acknowledgement.

Date 06.03.2019

Signature: 

Name: Sean Mark Dalziel

Date: 3rd JUNE 2019.

Witnesses:

Signature: _____

Name: _____

Address: _____

Signature: _____

Name: _____

Address: _____

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California

County of San Mateo)


On JUNE 3, 2019 before me, Rory Brennan, Notary Public,
(insert name and title of the officer)

personally appeared SEAN DALZIEL
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature RORY BRENNAN (Seal)



Global Blood Therapeutics, Inc. ("Assignee")

Signature: Tony Peng

Name: Tony Peng

Title: Vice President, Intellectual Property

Date: June 6, 2019

Witnesses:

Signature: _____

Name: _____

Address: _____

Signature: _____

Name: _____

Address: _____

Schedule A

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California
County of San Mateo


On June 6, 2019 before me, Alexandru Gurau, Notary Public
(insert name and title of the officer)

personally appeared Tony Peng
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.


I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature



(Seal)



Title	Country	Application No.	Filing Date	GBT No.	SMRH No.
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	African Regional IP Organization	AP/P/2019/011483	10-Apr-2019	GBT-16-003-AP	57LZ-259622-AP
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Argentina	P170102849	12-Oct-2017	GBT-16-003-AR	57LZ-259622-AR
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Brazil	BR112019006506-7	29-Mar-2019	GBT-16-003-BR	57LZ-259622-BR
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	European Patent Organization	17790926.4	09-May-2019	GBT-16-003-EP	57LZ-259622-EP
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Israel	265777	02-Apr-2019	GBT-16-003-IL	57LZ-259622-IL
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	India	201917015166	16-Apr-2019	GBT-16-003-IN	57LZ-259622-IN
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Mexico	MX/a/2019/004120	09-Apr-2019	GBT-16-003-MX	57LZ-259622-MX
TABLETS COMPRISING 2-	Nigeria	F/PT/C/201	29-	GBT-	57LZ-

Title	Country	Application No.	Filing Date	GBT No.	SMRH No.
HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE		9/3588	Mar-2019	16-003-NG	259622-NG
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	African Intellectual Property Organization	Not Yet Assigned	12-Apr-2019	GBT-16-003-OA	57LZ-259622-OA
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Oman	om/p/2019/00136	08-Apr-2019	GBT-16-003-OM	57LZ-259622-OM
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	USA	62/407406	12-Oct-2016	GBT-16-003-P	57LZ-259622-P
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	USA	62/553716	01-Sep-2017	GBT-16-003-P1	57LZ-259622-P2
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Qatar	QA/201904/000186	07-Apr-2019	GBT-16-003-QA	57LZ-259622-QA
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Saudi Arabia	519401517	09-Apr-2019	GBT-16-003-SA	57LZ-259622-SA
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	Taiwan	106134815	11-Oct-2017	GBT-16-003-TW	57LZ-259622-TW

Title	Country	Application No.	Filing Date	GBT No.	SMRH No.
5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE					
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	USA	15/782381	12-Oct-2017	GBT-16-003-US	57LZ-259622-US
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	World Intellectual Property Organization	PCT/US2017/056352	12-Oct-2017	GBT-16-003-PCT	57LZ-259622-WO
TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE	South Africa	2019/02296	11-Apr-2019	GBT-16-003-ZA	57LZ-259622-ZA